Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

HIV treatment news

Show

From To
A simple ask in 2016: the UN goal of universal HIV treatment

Last week, the working draft for 2016 UN Political Declaration on HIV/AIDS was released with only a few days for comments. Called the Zero draft, like previous statements produced every five years, it is a list of observations, comments and goals. But using the UN Statement as a platform of human rights has become disconnected from the scientific and medical advances in HIV over the last five years. The bulk of the draft document could have been written at any time during the epidemic, certainly most of it could have been written in 2011. There is only one reference to dramatic changes in the WHO 2015 guidelines and only two references to PrEP.

Published
28 April 2016
From
i-Base
Newly Diagnosed HIV+ Men Are Embracing Treatment More Than Ever Before

Gay and bisexual men who are newly diagnosed with HIV change their behaviour to reduce the chance of onward transmission, according to the results of a long-running Australian study released today. It found that more newly diagnosed men are adopting treatment as prevention (TasP) than ever before.

Published
26 April 2016
From
Star Observer
First in, best health: treat HIV now

It may be over 30 years since HIV hit the world, but it’s only recently that a study finally revealed the sooner a person diagnosed with HIV begins taking antiretroviral medication, the better it is for their long-term health outcomes. In light of this, the Victorian AIDS Council (VAC) and Living Positive Victoria (LPV) have teamed up to launch their first ever social marketing campaign dedicated solely to early treatment: Treat HIV Now.

Published
26 April 2016
From
Star Observer
European Commission Grants Marketing Authorization for Gilead’s Fixed-Dose Combination Descovy® (Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV

Gilead Sciences, Inc. today announced that the European Commission has granted marketing authorization for two doses of Descovy® (emtricitabine and tenofovir alafenamide 200/10 mg and 200/25 mg; F/TAF), a fixed-dose combination for the treatment of HIV-1 infection. Descovy is Gilead’s second TAF-based therapy to receive marketing authorization in the European Union.

Published
25 April 2016
From
Gilead press release
ViiV Healthcare, Medicines Patent Pool Extend Licence for Dolutegravir to All Lower Middle-Income Countries

The Medicines Patent Pool (MPP) and ViiV Healthcare announced an extension of their current licensing agreement today to increase access to dolutegravir (DTG), a promising new antiretroviral, to cover all remaining lower middle-income countries. The amendment to the 2014 licence specifically allows generic medicine distribution in four countries with patents - Armenia, Moldova, Morocco and Ukraine - that were not covered in the initial agreement. MPP sub-licensees can now sell in countries that are home to 94% of people living with HIV in the developing world.

Published
25 April 2016
From
ViiV Healthcare press release
Multiple social and health factors associated with irregular attendance at London HIV clinics

People who miss appointments for HIV care are more likely to have money problems, childcare responsibilities and a history of depression according to a recent UK study. While

Published
22 April 2016
By
Roger Pebody
AIDS Treatment in Haiti Promising for Developing Nations

One of the first groups of HIV patients in a poor country to get free AIDS drugs has about the same survival rate as their closest counterparts in the United States, according to scientists at Weill Cornell Medical College.

Published
19 April 2016
From
The New York Times
Outbreak of high level azithromycin resistant gonorrhoea in England

There have been 34 cases of high level azithromycin resistant gonorrhoea amongst residents of England between November 2014 and April 2016. The outbreak spread from the north of England to the West Midlands and south of England, including London. Initial cases were among heterosexuals but more recent evidence suggests high level azithromycin resistant gonorrhoea is now spreading among men who have sex with men.

Published
15 April 2016
From
Public Health England
People who use drugs still adherent to PrEP

New research conducted with a group of PrEP clients at the San Francisco AIDS Foundation PrEP clinic suggests that people who use substances adhere to PrEP and stay in care at about the same rate as people who do not use drugs.

Published
13 April 2016
From
BETA blog
People not taking HIV treatment feel under pressure to ‘do the right thing’

Australian people living with HIV who have chosen not to take antiretrovirals and who have doubts about HIV medicine report feeling excluded and silenced within HIV organisations

Published
13 April 2016
By
Roger Pebody

Filter by country